Evaluation of Disease Activity in Inflammatory Bowel Disease: Diagnostic Tools in the Assessment of Histological Healing

Abstract

Inflammatory bowel disease (IBD) comprises two types of chronic intestinal disorders: Crohn’s disease and ulcerative colitis. In long-standing ulcerative colitis disease activity, histological persistent inflammation has been linked to an increased risk of relapse, and long-term corticosteroid use, even when endoscopic remission is reached. In Crohn’s disease, the discontinuous nature of lesions and transmural inflammation have limited the standardized histological assessment. The current evidence from research proposes that besides clinical and endoscopic healing, the achievement of histological healing constitutes an endpoint to assess disease activity and remission in IBD patients concerning better long-term disease outcomes. Histological alterations may persist even in the absence of endoscopic lesions. For these reasons, new advanced techniques promise to revolutionize the field of IBD by improving the endoscopic and histologic assessment, disease characterization, and ultimately patient care, with an established role in daily practice for objective assessment of lesions. This review outlines the importance of including microscopic evaluation in IBD, highlighting the clinical benefits of a deep state of disease remission using validated diagnostic methods and scoring systems for daily clinical practice.

Crohn’s Disease and Ulcerative Colitis: From Pathophysiology to Novel Therapeutic Approaches

“…Additionally, there was notable heterogeneity in the sensitivity, specificity, and false-positive rates of fecal biomarkers, necessitating further research and validation. In another review, Jucan et al [ 13 ] (Contribution 2) introduced the concept of histological healing (HH) as a therapeutic target in IBD, associated with improved disease prognosis and a decrease in disease-related complications. This study underscores the need for validating and standardizing histological scores to more precisely define micro-activities in clinical practice and trials.…”